Chinese Biotech Firm Brags It’s Making Money “Screening Out” Babies With Down Syndrome
A Chinese biotech firm has declared “screening out” babies with Down’s syndrome is a “cash cow” funding the growth of the whole business. The admission comes from a spokesperson for BGI Group – a Chinese genetics conglomerate whose main business is offering non-invasive prenatal tests, primarily used to diagnose Down’s syndrome.